“Major Pharmacuetical Company Says – Our Drugs Do Not Work”

Majority of their products were ineffective for more than half of their consumers

The vice-president of a major pharmaceutical company recently went public, stating that the majority of their products were ineffective for more than half of their consumers. Some of the shocking statistics include:

  • Drugs for Alzheimer’s disease work in less than one in three patients
  • Drugs for cancer are effective in only 25% of patients
  • Drugs for migraines, osteoporosis and arthritis only work in half of the patients to which they’re prescribed
  • Diabetes drugs are on 57% effective
  • Antidepressants do not work for up to 48% of patients

He stated that the low number of patients the drugs worked for was because of genetic differences between patients. The statements and discoveries are leading to a developing area in pharmacology, known as ‘pharmacogenomics’, or the application of human genes for the development and testing of medications and drug products. It means that there’s the possibility that drugs will become more specific for a type of person (depending on the genetics) and therefore more likely to be effective. It moves away from the typical pharmaceutical aim, to make and sell drugs to as many people as possible. Dr Roses stated that ‘pharmacogenomics has the promise of removing much of the uncertainty’. However, this is in very early stages and something we are still yet to see available on the market.

Read the full article here: http://www.independent.co.uk/news/science/glaxo-chief-our-drugs-do-not-work-on-most-patients-5508670.html